Archives
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Harnessing Microtubule Dynamics for Precision Oncology: D...
2025-10-06
Explore how Docetaxel, a potent microtubulin disassembly inhibitor and cornerstone of taxane chemotherapy, is reshaping translational gastric cancer research. This thought-leadership article delivers mechanistic insights, strategic guidance for experimental design, and an integrative perspective on next-generation assembloid models, highlighting the clinical and translational potential of Docetaxel in unraveling drug resistance and optimizing personalized therapy.
-
LY2603618: Selective Chk1 Inhibitor for Cancer Chemothera...
2025-10-05
LY2603618 stands out as a next-generation selective checkpoint kinase 1 inhibitor that transforms non-small cell lung cancer research. By integrating ATP-competitive Chk1 inhibition with redox pathway modulation, it enables precise dissection of DNA damage response and enhances chemotherapy sensitivity far beyond traditional approaches.
-
Harnessing PARP-DNA Trapping: Strategic Insights for Tran...
2025-10-04
This thought-leadership article explores the advanced mechanistic underpinnings and translational strategies for BMN 673 (Talazoparib), a potent and selective PARP1/2 inhibitor. Integrating recent discoveries in BRCA2-RAD51 dynamics and PARP1-DNA complex trapping, the piece offers actionable guidance for researchers designing next-generation studies in homologous recombination deficient (HRD) cancers and beyond. By contextualizing BMN 673's capabilities within the competitive PARP inhibitor landscape and highlighting predictive biomarkers, the article delivers a visionary roadmap for advancing precision cancer therapy.
-
Sulfo-NHS-Biotin: Advanced Strategies for Single-Cell Sec...
2025-10-03
Discover cutting-edge applications of Sulfo-NHS-Biotin, a water-soluble biotinylation reagent, in high-resolution single-cell secretome analysis. This in-depth guide explores mechanisms, best practices, and transformative potential beyond conventional cell surface protein labeling.
-
Tetrandrine: Mechanistic Insights and Strategic Opportuni...
2025-10-02
This thought-leadership article delves into the multifaceted roles of Tetrandrine—an alkaloid calcium channel blocker—in modulating cell signaling pathways, advancing neuroscience and cancer biology, and driving innovation in translational research. Integrating mechanistic perspectives, competitive analysis, and actionable guidance, it provides researchers with a roadmap for leveraging Tetrandrine’s unique capabilities in the evolving biomedical landscape.
-
Bay 11-7821 (BAY 11-7082): Redefining the Frontiers of In...
2025-10-01
This thought-leadership article provides a mechanistic deep dive into Bay 11-7821 (BAY 11-7082), a selective IKK inhibitor at the nexus of NF-κB pathway inhibition, inflammasome modulation, and targeted cell death. By integrating recent discoveries in lactate-driven macrophage signaling and HMGB1 release, the article charts new territory for translational researchers and positions Bay 11-7821 as a cornerstone tool for next-generation studies in cancer and inflammatory disease.
-
Erastin: A Ferroptosis Inducer Transforming Cancer Biology
2025-09-30
Erastin stands out as a precise ferroptosis inducer, empowering researchers to dissect iron-dependent, non-apoptotic cell death mechanisms in RAS or BRAF-mutant tumors. Its robust selectivity, compatibility with advanced oxidative stress assays, and unique inhibition of cystine/glutamate antiporter system Xc⁻ position Erastin as an essential tool for translational cancer biology and therapy innovation.
-
N1-Methylpseudouridine: Precision mRNA Modification for T...
2025-09-29
Explore how N1-Methylpseudouridine advances mRNA translation enhancement and innate immune response modulation with a mechanistic focus on eIF2α phosphorylation and mitochondrial homeostasis. This in-depth article reveals new strategies for therapeutic protein expression and disease modeling, setting itself apart from prior mRNA research content.
-
VER 155008: Advanced HSP70 Inhibition for Disease Modeling
2025-09-28
Explore VER 155008, a potent HSP 70 inhibitor, and its unique role in dissecting heat shock protein signaling and apoptosis in advanced disease models. This article offers a deeper, translational perspective on Hsp70 chaperone pathway inhibition and its impact on protein phase separation, setting it apart from existing literature.
-
HyperScribe™ T7 Cy5 RNA Labeling Kit: Transforming RNA-Pr...
2025-09-27
Explore how the HyperScribe T7 High Yield Cy5 RNA Labeling Kit enables precise in vitro transcription RNA labeling for advanced RNA-protein interaction and phase separation research. Gain deep scientific insight into fluorescent nucleotide incorporation and probe design beyond conventional applications.
-
RSL3 and the Ferroptosis Frontier: Redefining Cell Death ...
2025-09-26
Explore how RSL3, a potent glutathione peroxidase 4 inhibitor, is revolutionizing cancer biology by revealing ferroptosis as a distinct, targetable form of non-apoptotic cell death. This comprehensive analysis uncovers emerging intersections with transcriptional apoptosis and highlights advanced research applications.
-
Clozapine N-oxide (CNO): Precision Chemogenetics for Anxi...
2025-09-25
Explore the advanced role of Clozapine N-oxide (CNO) in neuroscience as a selective chemogenetic actuator for dissecting anxiety-related circuits. This article uniquely bridges molecular pharmacology, circuit-level modulation, and translational insights, making it indispensable for GPCR signaling and schizophrenia research.
-
ISRIB (trans-isomer): Redefining Integrated Stress Respon...
2025-09-24
Explore how ISRIB (trans-isomer) advances integrated stress response inhibition, offering unique mechanistic insights and translational applications for ER stress research, liver fibrosis, and cognitive enhancement. This article reveals new frontiers in ISRIB’s use beyond previous reviews, with emphasis on eIF2B activation and ATF4 targeting.
-
Verapamil HCl: Novel Mechanisms in Osteoporosis and Infla...
2025-09-23
Explore how Verapamil HCl, a phenylalkylamine L-type calcium channel blocker, reveals new mechanistic insights in osteoporosis and arthritis inflammation models through TXNIP modulation and apoptosis induction.
-
The only psychostimulant treatment option in Turkey is methy
2025-03-03

The only psychostimulant treatment option in Turkey is methylphenidate (Çetin et al., 2015). It is broken down by carboxylase enzyme (CES1) (Sun et al., 2004). From the point of pharmacokinetics, it may be suggested that CES1 gene polymorphisms may be the key responsible factors in patients resistan
16484 records 8/1099 page Previous Next First page 上5页 678910 下5页 Last page